Substituted-1, 3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties
申请人:Belleau Bernard
公开号:US20070037977A1
公开(公告)日:2007-02-15
Disclosed are compounds of the formula
wherein
R
1
is hydrogen or an acyl group having 1 to 16 carbon atoms;
R
2
is a purine or pyrimidine base or an analogue or derivative thereof;
Z is O, S, S═O or SO
2
; and pharmaceutically acceptable derivatives thereof. Also, described are process for and intermediates of use in their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds in the antiviral treatment of mammals.
Substituted-1,3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties
申请人:Belleau Bernard
公开号:US20070037975A1
公开(公告)日:2007-02-15
Disclosed are compounds of the formula wherein R
1
is hydrogen or an acyl group having 1 to 16 carbon atoms;
R
2
is a purine or pyrimidine base or an analogue or derivative thereof;
Z is O, S, S═O or SO
2
; and pharmaceutically acceptable derivatives thereof. Also described are processes for and intermediates of use in their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds in the antiviral treatment of mammals.
Use of 5-Fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis B
申请人:EMORY UNIVERSITY
公开号:EP1142891A1
公开(公告)日:2001-10-10
The use of a 1,3-oxathiolane nucleoside analogue and pharmaceutically acceptable derivatives thereof for the treatment of hepatitis B virus infections is disclosed. Pharmaceutical formulations are also provided.
Use of 5-fluoro-2'-deoxy-3'-thiacytidine fo the treatment of hepatitis B
申请人:EMORY UNIVERSITY
公开号:EP1808434A2
公开(公告)日:2007-07-18
The use of a 1,3-oxathiolane nucleoside analogue and pharmaceutically acceptable derivatives thereof for the treatment of hepatitis B virus infections is disclosed. Pharmaceutical formulations are also provided.
The use of a 1,3-oxathiolane nucleoside analogue and pharmaceutically acceptable derivatives thereof for the treatment of hepatitis B virus infections is disclosed. Pharmaceutical formulations are also provided.